Metastatic pancreatic cancer is particularly resistant to chemotherapy. Currently available first-line, standard-of-care treatments are correlated with approximately six months of progression-free survival, and less than 10% of the patients can survive five years after the initial diagnosis. Loss-of-function mutations in breast cancer (BRCA) genes are associated with an increased risk of pancreatic cancer. Importantly, these germline mutations are sensitive to poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors such as Olaparib.
Evidence has suggested the clinical efficacy of Olaparib in patients with BRCA germline mutations and metastatic pancreatic cancer. For a better understanding of ‘Updates in Metastatic Pancreatic Cancer Management’, AstraZeneca and Docplexus have organized an interactive webinar with the experts in the field- Dr. Talia Golan and Dr. Raghav…
